Literature DB >> 6403466

Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.

W D Zollinger, R E Mandrell.   

Abstract

The bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide was investigated as a function of the complement source. The immunoglobulin M murine monoclonal antibody 2-2-B was shown by several different methods to be highly specific for meningococcal group B and Escherichia coli K1 capsular polysaccharides. It had strong bactericidal activity in conjunction with either rabbit or human complement, but gave a higher titer with rabbit complement. A strong prozone was observed in each case. Human postvaccination antibody to meningococcal group B polysaccharide was strongly bactericidal with rabbit complement, but had little or no bactericidal activity in conjunction with human complement. Antibodies in adult normal human sera that were bactericidal with rabbit complement were also found to be predominantly directed against the meningococcal group B capsular polysaccharide. Human antibodies that were bactericidal with human complement appeared to be primarily directed against noncapsular antigens.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6403466      PMCID： PMC264843          DOI： 10.1128/iai.40.1.257-264.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  33 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  Serotype determinant protein of Neisseria Meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells.

Authors:  T B Helting; G Guthöhrlein; F Blackkolb; H Ronneberger
Journal:  Acta Pathol Microbiol Scand C       Date:  1981-04

3.  Natural bactericidal activity of human serum against Neisseria meningitidis isolates of different serogroups and serotypes.

Authors:  D E Craven; K T Shen; C E Frasch
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

4.  Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants.

Authors:  R E Mandrell; W D Zollinger
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

5.  Analysis of outer membrane components of Escherichia coli ML308 225 and of a serum-resistant mutant.

Authors:  G L Tee; G K Scott
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

6.  Homologous species restriction in lysis of erythrocytes by terminal complement proteins.

Authors:  G M Hänsch; C H Hammer; P Vanguri; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

7.  ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes.

Authors:  B M Gray
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

8.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.

Authors:  W D Zollinger; R E Mandrell; J M Griffiss; P Altieri; S Berman
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

9.  Meningococcal meningitis in familial deficiency of the fifth component of complement.

Authors:  G Peter; M B Weigert; A R Bissel; R Gold; D Kreutzer; R H McLean
Journal:  Pediatrics       Date:  1981-06       Impact factor: 7.124

10.  Plasmid-determined resistance to serum bactericidal activity: a major outer membrane protein, the traT gene product, is responsible for plasmid-specified serum resistance in Escherichia coli.

Authors:  A Moll; P A Manning; K N Timmis
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441
View more
  72 in total

1.  Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.

Authors:  K T Mountzouros; A P Howell
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.

Authors:  Rohit K Katial; Brenda L Brandt; Ellen E Moran; Stephen Marks; Victor Agnello; Wendell D Zollinger
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine.

Authors:  Peter T Beernink; Jo Anne Welsch; Lee H Harrison; Arunas Leipus; Sheldon L Kaplan; Dan M Granoff
Journal:  J Infect Dis       Date:  2007-04-05       Impact factor: 5.226

5.  Importance of complement source in measuring meningococcal bactericidal titers.

Authors:  G F Santos; R R Deck; J Donnelly; W Blackwelder; D M Granoff
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

6.  Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen.

Authors:  S Harthug; E Rosenqvist; E A Høiby; T W Gedde-Dahl; L O Frøholm
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

7.  Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines.

Authors:  Kyoung Whun Kim; Soyoung Jeong; Ki Bum Ahn; Jae Seung Yang; Cheol-Heui Yun; Seung Hyun Han
Journal:  J Microbiol       Date:  2017-12-07       Impact factor: 3.422

8.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

9.  The identification of cryptic rhamnose biosynthesis genes in Neisseria gonorrhoeae and their relationship to lipopolysaccharide biosynthesis.

Authors:  B D Robertson; M Frosch; J P van Putten
Journal:  J Bacteriol       Date:  1994-11       Impact factor: 3.490

Review 10.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.